Publications

Preclinical
AACR
April 17, 2026
ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer
Lawn et al.
Preclinical
AACR
April 17, 2026
A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancers
Garnett et al.
Preclinical
AACR
April 17, 2026
ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers
Urosev et al.
Preclinical
AACR
April 17, 2026
Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer
Fung et al.
Preclinical
AACR
April 17, 2026
Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads
Petersen et al.
Preclinical, ZW191
AACR
April 17, 2026
ZW191 – a differentiated FRα-targeted topoisomerase I antibody-drug conjugate active in combination with standard of care drugs
Lawn et al.
Preclinical
Bioconjugate Chemistry
March 31, 2026
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In Vivo
Hernández Rojas et al.
Preclinical
ESMO TAT
March 18, 2026
Engineering trispecific and multivalent molecules: Design for selectivity and potency
Nina Weisser, Ph.D.
Preclinical
ADC Asia
March 11, 2026
Enhancing the therapeutic potential of topoisomerase 1 inhibitor ADCs: from concept to clinic
Paul Moore, Ph.D.
Preclinical
Festival of Biologics
March 5, 2026
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Robert Nechanitzky
Preclinical
Festival of Biologics
March 4, 2026
Engineering Next-Generation T Cell Engagers: A Trispecific Platform for Cancer Immunotherapy
Anna von Rossum, Ph.D.
Preclinical, ZW191
World ADC London
February 25, 2026
Design of ZW191: Preclinical Insights and Clinical Potential
Stuart Barnscher